Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:21 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 500288 | NSE: MOREPENLAB

Morepen Laboratories Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹55.24Undervalued by 48.49%vs CMP ₹37.20

P/E (26.7) × ROE (11.8%) × BV (₹21.80) × DY (0.54%)

₹31.25Overvalued by 15.99%vs CMP ₹37.20
MoS: -19% (Negative)Confidence: 53/100 (Moderate)Models: 2 Under, 1 Fair, 6 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹53.5322%Under (+43.9%)
Graham NumberEarnings₹29.8816%Over (-19.7%)
Earnings PowerEarnings₹10.9313%Over (-70.6%)
DCFCash Flow₹15.8713%Over (-57.3%)
Net Asset ValueAssets₹21.857%Over (-41.3%)
EV/EBITDAEnterprise₹34.179%Fair (-8.1%)
Earnings YieldEarnings₹18.207%Over (-51.1%)
ROCE CapitalReturns₹45.499%Under (+22.3%)
Revenue MultipleRevenue₹33.075%Over (-11.1%)
Consensus (9 models)₹31.25100%Overvalued
Key Drivers: Wide model spread (₹11–₹54) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -3.1%

*Investments are subject to market risks

Investment Snapshot

56
Morepen Laboratories Ltd scores 56/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health72/100 · Strong
ROCE 15.1% GoodROE 11.8% AverageD/E 0.03 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 35.7% Stable
Earnings Quality50/100 · Moderate
OPM stable around 10% Steady
Quarterly Momentum40/100 · Moderate
Revenue (4Q): 1% YoY FlatProfit (4Q): -21% YoY Declining
Industry Rank60/100 · Moderate
P/E 26.7 vs industry 53.8 Cheaper than peersROCE 15.1% vs industry 16.4% Average3Y sales CAGR: 5% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:21 am

Market Cap 2,038 Cr.
Current Price 37.2
Intrinsic Value₹31.25
High / Low 70.5/33.0
Stock P/E26.7
Book Value 21.8
Dividend Yield0.54 %
ROCE15.1 %
ROE11.8 %
Face Value 2.00
PEG Ratio-8.62

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Morepen Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Morepen Laboratories Ltd 2,038 Cr. 37.2 70.5/33.026.7 21.80.54 %15.1 %11.8 % 2.00
Solara Active Pharma Sciences Ltd 2,023 Cr. 459 734/422 3470.00 %6.01 %0.05 % 10.0
Panacea Biotec Ltd 1,992 Cr. 325 582/292 1350.00 %4.57 %4.92 % 1.00
Unichem Laboratories Ltd 2,100 Cr. 298 712/27820.0 3460.00 %6.24 %5.59 % 2.00
Hikal Ltd 1,972 Cr. 160 457/14678.9 96.90.88 %9.85 %7.38 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Morepen Laboratories Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 348364401422445423455438453466425412484
Expenses 328348375388394375404394417424401381438
Operating Profit 21162634514852443642243146
OPM % 6%4%7%8%11%11%11%10%8%9%6%7%10%
Other Income 13234435554304
Interest 1100211115444
Depreciation 77888106251691110
Profit before tax 14112129444248463526164635
Tax % 36%26%29%26%27%32%25%24%24%21%26%10%22%
Net Profit 981521322936352720114128
EPS in Rs 0.180.160.290.420.630.550.710.640.490.370.200.750.50

Last Updated: March 3, 2026, 8:16 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 2:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 3674014855956077698531,1881,5471,4181,6901,8121,787
Expenses 3183524245345427017851,0701,4101,3381,5321,6381,643
Operating Profit 4948626165686911913780159174143
OPM % 13%12%13%10%11%9%8%10%9%6%9%10%8%
Other Income 41-3444912106141843
Interest 1091084222-724817
Depreciation 46393534344037302828332947
Profit before tax -3213243029399912756135155122
Tax % 0%6%-1%0%0%1%14%1%20%31%29%24%
Net Profit -321324302934971023997118100
EPS in Rs -0.060.050.280.530.660.640.752.162.130.761.882.151.82
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%9%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)166.67%550.00%84.62%25.00%-3.33%17.24%185.29%5.15%-61.76%148.72%21.65%
Change in YoY Net Profit Growth (%)0.00%383.33%-465.38%-59.62%-28.33%20.57%168.05%-180.14%-66.92%210.48%-127.07%

Morepen Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: February 1, 2026, 1:05 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 909090909090909096102102110110
Reserves 8878911061361631943354836517451,0471,087
Borrowings 20920118716913413213317192529105158
Other Liabilities 103121156173226230246416473332417517381
Total Liabilities 4904895245385866156638581,0701,1101,2931,7781,736
Fixed Assets 368322297272264236216225252267307489471
CWIP 000000021417242826
Investments 0000001100185136
Other Assets 1211672272663213794466318048279601,1761,104
Total Assets 4904895245385866156638581,0701,1101,2931,7781,736

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 3451504163171151-60-917332
Cash from Investing Activity + -1-32-27-14-27-13-12-70-32-47-83-322
Cash from Financing Activity + -29-19-27-24-38-0547661445300
Net Cash Flow 4-0-43-14428-266-510
Free Cash Flow 29464131376-610-127-137-8-182
CFO/OP 69%105%81%66%98%26%25%44%-26%-94%70%40%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-160.00-153.00-125.00-108.00-69.00-64.00-64.00102.00118.0055.00130.0069.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 425166577364595659687065
Inventory Days 565551657669918296878594
Days Payable 116126140125173124113989087101114
Cash Conversion Cycle -17-20-23-3-249374065695445
Working Capital Days -21-20-10-86-62-34-817559894107
ROCE %1%3%8%9%9%8%10%23%23%8%17%15%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 38.22%38.22%38.22%38.22%38.22%38.22%35.66%35.66%35.66%35.66%35.66%35.66%
FIIs 0.96%1.00%1.29%2.11%1.85%1.67%2.08%2.22%1.94%1.72%1.62%1.62%
DIIs 2.93%2.32%2.27%2.21%2.15%2.14%1.69%1.64%1.67%1.50%1.49%1.25%
Government 0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public 57.88%58.45%58.20%57.46%57.76%57.96%60.57%60.46%60.72%61.09%61.22%61.46%
No. of Shareholders 3,06,1503,01,8323,04,0013,04,2893,36,0193,48,7664,30,9294,48,3614,68,8604,61,1804,61,8534,53,137

Shareholding Pattern Chart

No. of Shareholders

Morepen Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal BSE Healthcare ETF 4,401 0.16 0.024,4012025-04-22 16:00:160%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 2.201.880.772.262.16
Diluted EPS (Rs.) 2.201.880.771.962.16
Cash EPS (Rs.) 2.682.541.302.712.83
Book Value[Excl.RevalReserv]/Share (Rs.) 21.1016.5814.7212.109.43
Book Value[Incl.RevalReserv]/Share (Rs.) 21.1016.5814.7212.109.43
Revenue From Operations / Share (Rs.) 33.0633.0727.7332.3726.41
PBDIT / Share (Rs.) 3.513.381.683.082.90
PBIT / Share (Rs.) 2.982.721.132.502.23
PBT / Share (Rs.) 2.832.651.092.652.19
Net Profit / Share (Rs.) 2.151.890.752.132.16
NP After MI And SOA / Share (Rs.) 2.151.880.752.132.16
PBDIT Margin (%) 10.6210.216.049.5010.99
PBIT Margin (%) 9.028.234.077.718.44
PBT Margin (%) 8.568.013.938.198.29
Net Profit Margin (%) 6.515.712.726.578.17
NP After MI And SOA Margin (%) 6.515.682.726.578.17
Return on Networth / Equity (%) 10.2011.345.1317.5722.85
Return on Capital Employeed (%) 12.7915.617.3119.4422.07
Return On Assets (%) 6.637.433.489.5011.31
Long Term Debt / Equity (X) 0.020.000.000.000.00
Total Debt / Equity (X) 0.060.030.030.030.03
Asset Turnover Ratio (%) 1.181.411.301.601.47
Current Ratio (X) 2.322.212.351.611.30
Quick Ratio (X) 1.721.591.641.000.87
Inventory Turnover Ratio (X) 6.603.703.103.534.01
Interest Coverage Ratio (X) 23.0746.5243.25-19.9673.02
Interest Coverage Ratio (Post Tax) (X) 15.1527.0420.53-12.8155.29
Enterprise Value (Cr.) 2682.562126.721280.991720.861393.88
EV / Net Operating Revenue (X) 1.481.260.901.111.17
EV / EBITDA (X) 13.9412.3214.9511.7110.67
MarketCap / Net Operating Revenue (X) 1.451.270.921.131.22
Price / BV (X) 2.272.541.743.023.40
Price / Net Operating Revenue (X) 1.451.270.921.131.22
EarningsYield 0.040.040.020.050.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Morepen Laboratories Ltd. is a Public Limited Listed company incorporated on 01/12/1984 and has its registered office in the State of Himachal Pradesh, India. Company's Corporate Identification Number(CIN) is L24231HP1984PLC006028 and registration number is 006028. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1554.54 Cr. and Equity Capital is Rs. 109.58 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsMorepen Village, Solan District Himachal Pradesh 173205Contact not found
Management
NamePosition Held
Mr. Sushil SuriChairman & Managing Director
Mr. Sanjay SuriWhole Time Director
Mr. Praveen Kumar DuttIndependent Director
Dr.(Mrs.) SavitaIndependent Director
Mr. Ranjit KhattarIndependent Director
Mr. Sharad JainIndependent Director

FAQ

What is the intrinsic value of Morepen Laboratories Ltd and is it undervalued?

As of 08 April 2026, Morepen Laboratories Ltd's intrinsic value is ₹31.25, which is 15.99% lower than the current market price of ₹37.20, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (11.8 %), book value (₹21.8), dividend yield (0.54 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Morepen Laboratories Ltd?

Morepen Laboratories Ltd is trading at ₹37.20 as of 08 April 2026, with a FY2026-2027 high of ₹70.5 and low of ₹33.0. The stock is currently near its 52-week low. Market cap stands at ₹2,038 Cr..

How does Morepen Laboratories Ltd's P/E ratio compare to its industry?

Morepen Laboratories Ltd has a P/E ratio of 26.7, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Morepen Laboratories Ltd financially healthy?

Key indicators for Morepen Laboratories Ltd: ROCE of 15.1 % indicates efficient capital utilization. Dividend yield is 0.54 %.

Is Morepen Laboratories Ltd profitable and how is the profit trend?

Morepen Laboratories Ltd reported a net profit of ₹118 Cr in Mar 2025 on revenue of ₹1,812 Cr. Compared to ₹102 Cr in Mar 2022, the net profit shows an improving trend.

Does Morepen Laboratories Ltd pay dividends?

Morepen Laboratories Ltd has a dividend yield of 0.54 % at the current price of ₹37.20. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Morepen Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports